Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q1 2020 · 10-Q
Revenue$1.33M$1.33M−53.1% vs Q1 2019 Net Income-$32.54M-$32.54MN/M vs Q1 2019 EPS Diluted-$0.26-$0.26N/M vs Q1 2019 Operating Income-$25,232,268N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
Free Cash Flowderived-$25,593,673N/M Margins · derivedOperating margin-1901.1%−892.7 pt vs Q1 2019
Net margin-2451.7%−1419.2 pt vs Q1 2019
ended Mar 31, 2020 · filed May 11, 2020 · 41 d after period end